SCHEMBL643177

SCHEMBL643177

OCCc1cccc(Br)c1

nearest known ligand 0.63

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 4/20 0.63
TDP1 Q9NUW8 2/20 0.52
IDO1 P14902 2/20 0.50
AGXT P21549 2/20 0.50
CYP4F2 P78329 2/20 0.47
CYP4A11 Q02928 2/20 0.47
MAOB P27338 1/20 0.47
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
ALOX5 P09917 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
BACE1 P56817 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alcohol SCHEMBL7528524 0.94 TAAR1 (0.57) TAAR1TDP1IDO1AGXTCYP4F2
SCHEMBL81535 0.87 TAAR1 (0.59) TAAR1IDO1AGXTCYP4F2CYP4A11
SCHEMBL4399626 0.85 TAAR1 (0.74) TAAR1TDP1IDO1AGXTMAOB
SCHEMBL1047547 0.85 TAAR1 (0.57) TAAR1IDO1AGXTCYP4F2CYP4A11
SCHEMBL1045131 0.84 TAAR1 (0.55) TAAR1IDO1AGXTCYP4F2CYP4A11
SCHEMBL3456345 0.84 TAAR1 (0.55) TAAR1IDO1AGXTCYP4F2CYP4A11
SCHEMBL239199 0.83 TDP1 (0.65) TAAR1TDP1CYP4F2CYP4A11MAOB
SCHEMBL93041 0.81
SCHEMBL5240585 0.81 TAAR1 (0.68) TAAR1TDP1IDO1AGXTMAOB
SCHEMBL2185705 0.81 TAAR1 (0.52) TAAR1IDO1AGXTMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 769 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114315658-B Preparation method of sulfonate alkane ester 宁波南大光电材料有限公司 2023-06-30 CN claimed
CN-114315658-A Preparation method of sulfonate alkane ester 宁波南大光电材料有限公司 2022-04-12 CN claimed
CN-114213213-A Preparation method of fingolimod impurity 深圳市祥根生物医药有限公司 2022-03-22 CN claimed
CN-113333018-A Preparation method and application of supported catalyst for preparing halogenated styrene 中触媒新材料股份有限公司 2021-09-03 CN claimed
US-6989052-B1 Phase change ink printing process XEROX CORPORATION (US) 2006-01-24 US claimed
US-20060004123-A1 PHASE CHANGE INK PRINTING PROCESS XEROX CORPORATION 2006-01-05 US claimed
US-4255340-A Method for preparing an alkenyl-substituted dicarboxylic acid anhydride TEXACO INC. (US) 1981-03-10 US claimed
US-12503452-B2 Antimicrobial compounds and methods CURZA GLOBAL, LLC (US) 2025-12-23 US disclosed
US-12497382-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2025-12-16 US disclosed
WO-2025235840-A1 ECHINOCANDIN-LIKE AND BORON-CONTAINING ECHINOCANDIN COMPOUNDS AND THEIR USE AS AGROCHEMICAL FUNGICIDES 5METIS, INC. (US) 2025-11-13 WO disclosed
WO-2025137541-A1 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2025-06-26 WO disclosed
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 EP disclosed
US-20250188110-A1 SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) 2025-06-12 US disclosed
WO-1995018118-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS THE UPJOHN COMPANY (US) 1995-07-06 WO disclosed
EP-0536713-A1 Oxazole and imidazole derivatives as prostaglandin analogs E.R. SQUIBB & SONS, INC. (US) 1993-04-14 EP disclosed
EP-0251775-B1 ALPHA-ARYL-ALPHA-PHENYLETHYL-1H-1,2,4-TRIAZOLE-1-PROPANENITRILES ROHM AND HAAS COMPANY (US) 1993-01-20 EP disclosed
US-5153327-A 7-Oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease E. R. SQUIBB & SONS, INC. (US) 1992-10-06 US disclosed
US-5100889-A Thromboxane A2 receptor antagonists, thromboxane synthetase inhibitor E. R. SQUIBB & SONS, INC. (US) 1992-03-31 US disclosed
US-5087635-A Funcicides ROHM AND HAAS COMPANY (US) 1992-02-11 US disclosed
EP-0251775-A2 Alpha-aryl-alpha-phenylethyl-1H-1,2,4-triazole-1-propanenitriles ROHM AND HAAS COMPANY (US) 1988-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188110-A1 SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION KMT5A, KMT5B, KMT5C TAAR1 3002/4885TDP1 1179/4885IDO1 2116/4885
US-12497382-B2 GLP-1R modulating compounds GLP1R, GIPR, GPR119 TAAR1 1614/4885TDP1 3351/4885IDO1 4145/4885
US-12503452-B2 Antimicrobial compounds and methods MPO, NISCH, RPN2 TAAR1 4825/4885TDP1 4219/4885IDO1 1403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.